Defer or treat? Reasons for treatment decisions in patients with chronic hepatitis C genotype 1 in the early era of directly acting antiviral agents

Digestive and Liver Disease

Volumn 46, Issue 1, 2014, Pages 67-71

  Kittner, Jens M ^a   Weiss, Nora M ^a   Wiltink, Jörg ^a   Schattenberg, Jörg M ^a   Grambihler, Annette ^a   Thieringer, Florian ^a   Weinmann, Arndt ^a   Zimmermann, Tim ^a   Koch, Sandra ^a   Schuchmann, Marcus ^a   Galle, Peter R ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

Boceprevir; Chronic hepatitis C genotype 1; DAAs; Real life data; Telaprevir; Therapy decision

Indexed keywords

BOCEPREVIR; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; TELAPREVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DISEASE COURSE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MEDICATION COMPLIANCE; MIDDLE AGED; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNSPECIFIED SIDE EFFECT;

BOCEPREVIR; CHRONIC HEPATITIS C GENOTYPE 1; DAAS; REAL-LIFE DATA; TELAPREVIR; THERAPY DECISION;

ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DECISION MAKING; DISEASE PROGRESSION; DRUG CARRIERS; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OLIGOPEPTIDES; PATIENT PREFERENCE; POLYETHYLENE GLYCOLS; PROLINE; PROSPECTIVE STUDIES; RIBAVIRIN; SEVERITY OF ILLNESS INDEX; TIME FACTORS; WATCHFUL WAITING;

EID: 84892367839     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.08.139     Document Type: Article

References (26)

1. Vietri J., Prajapati G., Khoury A. The burden of hepatitis C in Europe from the patients' perspective: a survey in 5 countries. BMC Gastroenterology 2013, 13:16.
2. Manns M.P., Wedemeyer H., Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006, 55:1350-1359.
3. Pearlman B.L. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. The Lancet Infectious Diseases 2012, 12:717-728.
4. Jacobson I.M., McHutchison J.G., Dusheiko G., et al. Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011, 364:2405-2416.
5. Zeuzem S., Andreone P., Pol S., et al. Telaprevir for retreatment of HCV infection. The New England Journal of Medicine 2011, 364:2417-2428.
6. Poordad F., McCone J., Bacon B.R., et al. Boceprevir for untreated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364:1195-1206.
7. Bacon B.R., Gordon S.C., Lawitz E., et al. Boceprevir for previously treated chronic HCV genotype 1 infection. The New England Journal of Medicine 2011, 364:1207-1217.
8. Berg T., Buggisch P., Hueppe D., et al. Real-life data of telaprevir-based triple-therapy in patients with chronic hepatitis C GT1 in Germany - an interim analysis. Journal of Hepatology 2013, 58(Suppl. 1):S324.
9. Vezali E., Aghemo A., Colombo M. A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clinical Therapeutics 2010, 32:2117-2138.
10. Fontaine H., Hezode C., Dorival C., et al. SVR12 rates and safety of triple therapy including telaprevir or boceprevir in 221 cirrhotic non responders treated in the French early access program (ANRS CO20-CUPIC). Journal of Hepatology 2013, 58(Suppl. 1):S 27.
11. Lange C.M., Zeuzem S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. Journal of Hepatology 2013, 58:583-592.
12. Kowdley K.V., Lawitz E., Poordad F., et al. Safety and efficacy of interferon-free regimens of ABT-450/r, ABT-267, ABT-333+/- ribavirin in patients with chronic HCV GT1 infections: results from the AVIATOR study. Journal of Hepatology 2013, 58(Suppl. 1):S2.
13. EASL clinical practice guidelines: management of hepatitis C virus infection. Journal of Hepatology 2011;55.
14. Djulbegovic B., Hozo I., Beckstead J., Tsalatsanis A., Pauker S.G. Dual processing model of medical decision-making. BMC Medical Informatics and Decision Making 2012, 12:94.
15. Marcum J.A. An integrated model of clinical reasoning: dual-process theory of cognition and metacognition. Journal of Evaluation in Clinical Practice 2012, 18:954-961.
16. Maasoumy B., Port K., Markova A.A., et al. Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PloS One 2013, 8:e55285.
17. Chen E.Y., Sclair S.N., Czul F., et al. A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 2013, 26:445-453.
18. Aleman S., Rahbin N., Weiland O., et al. A risk for hepatocellular carcinoma still persists long-term after sustained virological response in patients with hepatitis C associated liver cirrhosis. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America 2013, 57:230-236.
19. Shiffman M.L., Benhamou Y. Patients with HCV and F1 and F2 fibrosis stage: treat now or wait?. Liver International: Official Journal of the International Association for the Study of the Liver 2013, 33(Suppl. 1):105-110.
20. Rutter K., Ferlitsch A., Maieron A., et al. Safetey of triple therapy with telaprevir or boceprevir in hepatitis C patients with advanced liver disease-predictive factors for sepsis. Journal of Hepatology 2013, 58(Suppl. 1):S30.
21. Poordad F., Bronowicki J.-P., Gordon S.C., et al. Factors that predict response of patients with hepatitis C virus infection to boceprevir. Gastroenterology 2012, 143:608-618.e5.
22. Cooper C., Lester R., Thorlund K., et al. Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysis. QJM: Monthly Journal of the Association of Physicians 2013, 106:153-163.
23. Sitole M., Silva M., Spooner L., Comee M.K., Malloy M. Telaprevir versus boceprevir in chronic hepatitis C: a meta-analysis of data from phase II and III trials. Clinical Therapeutics 2013, 35:190-197.
24. Benito J.M., Sánchez-Parra C., Maida I., et al. Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. Antiviral Therapy 2013, [Epub ahead of print].
25. Roujeau J.-C., Mockenhaupt M., Tahan S.R., et al. Telaprevir-related dermatitis. JAMA Dermatology (Chicago, III) 2013, 149:152-158.
26. FDA Drug Safety Communication: Serious skin reactions after combination treatment with the Hepatitis C drugs Incivek (telaprevir), peginterferon alfa, and ribavirin. Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm332860.htm.